Ingredients For A Qui Tam Suit: GSK’s Cidra Plant Violations
You may also be interested in...
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.
Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.
A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.